Skip to main content
ADIAL PHARMACEUTICALS, INC. logo

ADIAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ADIL ISIN · US00688A1060 US Manufacturing
Filings indexed 519 across all filing types
Latest filing 2026-03-03 Regulatory Filings
Country US United States of America
Listing US ADIL

About ADIAL PHARMACEUTICALS, INC.

https://www.adialpharma.com/

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The company's lead investigational drug candidate is AD04, a genetically targeted, serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder (AUD). AD04 is being developed in conjunction with a proprietary companion diagnostic genetic test. This test is designed to identify patients with specific genotypes who are most likely to respond to the treatment, representing a personalized medicine approach to managing addiction.

Recent filings

Filing Released Lang Actions
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
Regulatory Filings
2026-03-03 English
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
Regulatory Filings
2026-02-24 English
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
Regulatory Filings
2026-02-04 English
CURRENT REPORT
Regulatory Filings
2026-01-06 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2026-01-06 English
PRELIMINARY PROXY STATEMENT
Regulatory Filings
2025-12-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.